Peptides DB
Research-centric peptide and protocol reference hub

ARA 290 vs Oxytocin

Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team

ARA 290: Research use — not FDA-approvedOxytocin: FDA-approved

A data-driven comparison of ARA 290 and Oxytocin (also searched as Oxytocin vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

ARA 290 centers on healing, while Oxytocin leans toward neuro. On indexed research, Oxytocin is ahead (ARA 290: 13 studies, Human evidence; Oxytocin: 17, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • ARA 290 is strongest for healing; Oxytocin for neuro.
  • Evidence: ARA 290 Human evidence (13 studies) vs Oxytocin Human evidence (17).
  • Check the FDA-approval status chips above before assuming a legal use pathway.

Effect profiles, overlaid

ARA 290: Healing 4.0, Muscle 0.0, Metabolic 0.0, Neuro 4.0, Sleep 0.0, Immune 3.0, Skin 0.0 — Oxytocin: Healing 2.0, Muscle 0.0, Metabolic 0.0, Neuro 4.0, Sleep 1.0, Immune 1.0, Skin 0.0Healing & recovery — 4.0 / 5 · ARA 290Neuro & mood — 4.0 / 5 · ARA 290Inflammation & immune — 3.0 / 5 · ARA 290Healing & recovery — 2.0 / 5 · OxytocinNeuro & mood — 4.0 / 5 · OxytocinSleep & circadian — 1.0 / 5 · OxytocinInflammation & immune — 1.0 / 5 · OxytocinHealingMuscleMetabolicNeuroSleepImmuneSkin
ARA 290Oxytocin

At a glance

ARA 290Human evidence

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Strongest: HealingStudies: 13Level: Extensively Studied
OxytocinHuman evidence

Neurohypophysial Peptide | Social Bonding & Reproductive Hormone

Strongest: NeuroStudies: 17Level: FDA Approved

ARA 290 vs Oxytocin: side-by-side

MetricARA 290Oxytocin
ClassHealingHormonal
Regulatory statusResearch use onlyFDA-approved
Evidence gradeHuman evidenceHuman evidence
Studies indexed1317
Research levelExtensively StudiedFDA Approved
Strongest effectHealing & recoveryNeuro & mood
Healing & recovery4.02.0
Muscle & body comp0.00.0
Metabolic & appetite0.00.0
Neuro & mood4.04.0
Sleep & circadian0.01.0
Inflammation & immune3.01.0
Skin & aesthetics0.00.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyARA 290Oxytocin
Mechanismβ-common receptor interactionOxytocin receptor agonist
RouteIntravenous injection; Subcutaneous injection; Intranasal administration
Half-life~3-5 min
Time to peak~30 min
Duration of action1-2 hours

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Oxytocin?

### Oxytocin Summary Oxytocin is a neuropeptide that plays a crucial role in social bonding, reproductive behaviors, and emotional regulation. Its functions extend to various physiological processes, including childbirth and lactation, and it has garnered interest for its potential therapeutic applications in mental health and social disorders.

Full Oxytocin profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingARA 2904.0/5 effect signal
NeuroEvenBoth ~4.0/5
SleepOxytocin1.0/5 effect signal
InflammationARA 2903.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack ARA 290 and Oxytocin?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

ARA 290 vs Oxytocin: side effects

ARA 290

No community-reported effects logged yet.

Oxytocin

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

ARA 290 has 13 approved studies indexed (Human evidence), and Oxytocin has 17 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is ARA 290 or Oxytocin better?

It depends on your goal. ARA 290 is strongest for healing; Oxytocin for neuro. Oxytocin has more indexed studies (17). See the goal-by-goal breakdown above.

Which has more research, ARA 290 or Oxytocin?

ARA 290 has 13 approved studies indexed (Human evidence); Oxytocin has 17 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack ARA 290 and Oxytocin?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of ARA 290 vs Oxytocin?

ARA 290: no community-reported effects logged yet. Oxytocin: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is ARA 290 or Oxytocin FDA-approved?

ARA 290 is a research-use compound and is not FDA-approved. Oxytocin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Oxytocin better than ARA 290?

For neuro, Oxytocin has the edge; for healing, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.